HR/PR+ patients can be successfully treated with ER antagonists like tamoxifen or aromatase inhibitors, while HER2+ BC patients receive treatment with antibodies or other compounds targeting the HER2 pathways, such as trastuzumab, pertuzumab, and lapatinib [13]. This evidence concerns the gene ESR1 and breast cancer.